This trial is testing a new cancer vaccine in people with a certain type of cancer that has spread or cannot be removed by surgery. The vaccine will be given with two other drugs, and the goal is to see if it is safe and causes T cells to respond.
3 Primary · 7 Secondary · Reporting Duration: 4 years
12 Total Participants · 1 Treatment Group
Primary Treatment: DNAJB1-PRKACA peptide vaccine · No Placebo Group · Phase 1
Age Any Age · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: